**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 59400

**Manuscript Type:** CASE REPORT

**Nafamostat mesylate-induced hyperkalemia in critically ill patients with COVID-19: Four case reports**

Okajima M *et al*. Nafamostat and hyperkalemia in COVID-19 patients

Masaki Okajima, Yoshinori Takahashi, Takaaki Kaji, Naohiko Ogawa, Hideyuki Mouri

**Masaki Okajima, Hideyuki Mouri,** Intensive Care Unit, Kanazawa University Hospital, Kanazawa 920-8641, Ishikawa, Japan

**Yoshinori Takahashi,** Department of Rheumatology, Kanazawa University Hospital, Kanazawa 920-8641, Ishikawa, Japan

**Takaaki Kaji,** Department of Nephrology, Kanazawa University Hospital, Kanazawa 920-8641, Ishikawa, Japan

**Naohiko Ogawa,** Department of Respiratory Medicine, Kanazawa University Hospital, Kanazawa 920-8641, Ishikawa, Japan

**Author contributions:** Okajima M and Mouri H designed the study, had full access to all the study data, and take responsibility for the integrity and accuracy of the data; Kaji T contributed to data collection and analyzed the mechanism of hyperkalemia; Ogawa N played a role in managing treatment using nafamostat mesylate; Takahashi Y supervised this study and contributed to the writing of the manuscript; all authors contributed to data acquisition, data analysis, or data interpretation and approved the final version of the manuscript.

**Corresponding author: Masaki Okajima, MD, PhD, Assistant Professor,** Intensive Care Unit, Kanazawa University Hospital, 13-1 Takara-machi, Kanazawa 920-8641, Ishikawa, Japan. mmokaji@gmail.com

**Received:** September 10, 2020

**Revised:** October 1, 2020

**Accepted:** October 20, 2020

**Published online:**

**Abstract**

BACKGROUND

Nafamostat mesylate (NM) may prove to be one of the key drugs effective against coronavirus disease 2019 (COVID-19) because of its anti-viral properties and the potential to manage coagulopathy. However, NM tends to increase serum potassium levels.

CASE SUMMARY

We observed hyperkalemia immediately after NM administration (200 mg/d) in four consecutive patients who were admitted to the Kanazawa University Hospital with severe COVID-19 pneumonia. Urinary potassium excretion decreased after NM administration in three patients who underwent urinalysis.

CONCLUSION

NM is likely to produce hyperkalemia in patients with COVID-19. Therefore, it is necessary to monitor serum potassium values closely after NM initiation in COVID-19 patients who need respiratory support.

**Key Words:** COVID-19; Nafamostat; Hyperkalemia; Disseminated intravascular coagulation; Respiratory insufficiency; Case report

Okajima M, Takahashi Y, Kaji T, Ogawa N, Mouri H. Nafamostat mesylate-induced hyperkalemia in critically ill patients with COVID-19: Four case reports. *World J Clin Cases* 2020; In press

**Core Tip:** The coronavirus disease 2019 (COVID-19) pandemic is a rapidly evolving situation. Nafamostat mesylate (NM) may prove to effective against COVID-19. However, our case series shows NM-induced hyperkalemia in 4 patients with COVID-19. Monitoring serum potassium levels after NM-initiation is imperative.

**INTRODUCTION**

The pathophysiology of coronavirus disease 2019 (COVID-19) is still unclear; however, coagulopathy, an important mechanism of severe respiratory failure, has been observed in many severe COVID-19 cases and is associated with high mortality[1]. Therefore, managing coagulopathy is an important therapeutic target in severe COVID-19 cases.

Nafamostat mesylate (NM) is a serine protease inhibitor that inhibits proteolytic enzymes, such as thrombin, plasmin, and trypsin, and has been used for several decades in Japan for disseminated intravascular coagulation (DIC) and pancreatitis treatment.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been reported to enter epithelial cells *via* transmembrane protease serine 2 (TMPRSS2), which is inhibited by NM[2]. Additionally, coagulopathy in COVID-19 is characterized by enhanced fibrinolysis, which is treatable with NM[3]. Therefore, NM is anticipated to be a key drug against COVID-19.

However, NM has several side effects, with the most frequently observed side effect being hyperkalemia. We observed hyperkalemia immediately after NM administration in four consecutive patients who were admitted to the Kanazawa University Hospital between April 15 and April 27, 2020 with severe COVID-19 pneumonia and were treated with NM 200 mg/d for intravascular coagulopathy.

**CASE PRESENTATION**

***Chief complaints***

Patient 1 suffered from fever, dyspnea and diarrhea. Patient 2 had cough and sore throat. Patient 3 gradually developed cough, loss of appetite and malaise. Patient 4 suffered from fever, cough, sore throat, dyspnea and diarrhea.

***History of present illness***

As described above.

***History of past illness***

Patient 2 had hypertension and patient 4 had diabetes mellitus. Others had no history of past illness.

***Personal and family history***

As described above.

***Physical examination***

Not applicable.

***Laboratory examinations***

Their characteristics before NM administration are shown in Table 1. Levels of fibrin degradation products, fibrin degradation product D-dimer, and fibrinogen were elevated in all the patients. All required invasive mechanical ventilation, while two patients additionally required veno-venous extracorporeal membrane oxygenation after several days. No patient had chronic kidney disease and diarrhea; one patient was administered an angiotensin II receptor blocker, which is a potent drug that increases serum potassium levels. All four patients developed hyperkalemia (> 6 mEq/L in two patients) immediately after NM administration, without any acute kidney injuries (Figure 1). Three patients underwent urinalysis, and the urinary potassium levels were found to be relatively low; their potassium balance was positive, considering serum potassium levels were high in all of them. In the fourth patient, the transtubular potassium gradient was examined and found to be low (< 6).

***Imaging examinations***

Not applicable.

**FINAL DIAGNOSIS**

All four patients were diagnosed with NM-induced hyperkalemia.

**TREATMENT**

As indicated in Table 1, all patients required antihyperkalemic therapy including potassium intake reduction, furosemide administration, and glucose-insulin therapy.

**OUTCOME AND FOLLOW-UP**

Serum potassium levels were normalized after administration of NM was stopped in all patients.

**DISCUSSION**

NM may be suitable against COVID-19 infection as it can effectively block the SARS-CoV-2 entry *via* inhibition of TMPRSS2, and possesses antifibrinolytic qualities that may treat intravascular coagulation with enhanced fibrinolysis observed in COVID-19 patients. However, NM tends to increase serum potassium levels. Generally, NM causes hyperkalemia in 0.19% of patients with pancreatitis and in 4.75% with DIC. The required dose of NM is higher for DIC patients [0.06-0.20 mg/(kg·h)] than pancreatitis patients (10-20 mg/d)[4]. Our four patients received NM at a dose of 0.13-0.16 mg/(kg·h), which is equivalent to the dose used for DIC. However, we observed hyperkalemia immediately after NM administration in all four patients, which is a higher rate than has been previously reported.

NM and its metabolites have been reported to cause hyperkalemia by inhibiting aldosterone, Na-K ATPase activity in urinary tubules, and amiloride-sensitive sodium conductance in the cortical collecting duct, resulting in the reduction of urinary potassium excretion[5]. Our findings also indicate a decrease in urinary potassium excretion after NM administration. SARS-CoV-2 has been reported to be excreted in the urine and exists in the urinary tubules of patients with severe COVID-19[6]. Therefore, SARS-CoV-2 could enhance NM-induced hyperkalemia by inhibiting Na-K ATPase activity or amiloride-sensitive sodium conductance, especially in patients with severe COVID-19 who need respiratory support.

**CONCLUSION**

This is the first report to suggest that NM is likely to produce hyperkalemia in patients with COVID-19. Therefore, we need to monitor serum potassium values closely after NM initiation in COVID-19 patients.

**ACKNOWLEDGEMENTS**

We would like for the following collaborating author names from COVSAT-KUH (Special Assistant Team against COVID-19 at the Kanazawa University Hospital) Study Group to be searchable through their individual PubMed records: Endo I, Takashima S, Okada H, Oishi M, Yoshio T and Takago S.

**REFERENCES**

1 **Zhang L**, Yan X, Fan Q, Liu H, Liu X, Liu Z, Zhang Z. D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19. *J Thromb Haemost* 2020; **18**: 1324-1329 [PMID: 32306492 DOI: 10.1111/jth.14859]

2 **Yamamoto M**, Kiso M, Sakai-Tagawa Y, Iwatsuki-Horimoto K, Imai M, Takeda M, Kinoshita N, Ohmagari N, Gohda J, Semba K, Matsuda Z, Kawaguchi Y, Kawaoka Y, Inoue JI. The Anticoagulant Nafamostat Potently Inhibits SARS-CoV-2 S Protein-Mediated Fusion in a Cell Fusion Assay System and Viral Infection In Vitro in a Cell-Type-Dependent Manner. *Viruses* 2020; **12**: [PMID: 32532094 DOI: 10.3390/v12060629]

3 **Asakura H**, Ogawa H. Potential of heparin and nafamostat combination therapy for COVID-19. *J Thromb Haemost* 2020; **18**: 1521-1522 [PMID: 32302456 DOI: 10.1111/jth.14858]

4 **Nishimura H**, Yamaya M. A Synthetic Serine Protease Inhibitor, Nafamostat Mesilate, Is a Drug Potentially Applicable to the Treatment of Ebola Virus Disease. *Tohoku J Exp Med* 2015; **237**: 45-50 [PMID: 26346967 DOI: 10.1620/tjem.237.45]

5 **Muto S**, Imai M, Asano Y. Mechanisms of hyperkalemia caused by nafamostat mesilate. *Gen Pharmacol* 1995; **26**: 1627-1632 [PMID: 8745149 DOI: 10.1016/0306-3623(95)00072-0]

6 **Nomoto H**, Ishikane M, Katagiri D, Kinoshita N, Nagashima M, Sadamasu K, Yoshimura K, Ohmagari N. Cautious handling of urine from moderate to severe COVID-19 patients. *Am J Infect Control* 2020; **48**: 969-971 [PMID: 32502614 DOI: 10.1016/j.ajic.2020.05.034]

**Footnotes**

**Informed consent statement:** This case series was approved by the Institutional Review Board of the University of Kanazawa, No. 3438. All the reported individuals provided consent to participate in accordance with the Declaration of Helsinki.

**Conflict-of-interest statement:** The authors declare that they have no competing interests.

**CARE Checklist (2016) statement:** The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Peer-review started:** September 10, 2020

**First decision:** September 23, 2020

**Article in press:**

**Specialty type:** Medicine, research and experimental

**Country/Territory of origin:** Japan

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Liu YC **S-Editor:** Gao CC **L-Editor: P-Editor:**

**Figure Legends**



**Figure 1 Changes in serum potassium and creatinine levels before and during nafamostat mesylate administration.** Serum potassium levels increased in all four patients on the third day of NM administration without acute kidney disease. A: Serum potassium; B: Serum creatinine. Cre: Creatinine; NM: Nafamostat mesylate; K: Potassium.

**Table 1 Characteristics at baseline, before and during nafamostat mesylate administration**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Patient**  |  |  |  |
| **Baseline** | **1** | **2** | **3** | **4** |
| Age (yr) | 63 | 58 | 54 | 60 |
| Gender | Male | Female | Male | Female |
| Height (m) | 1.67 | 1.5 | 1.78 | 1.52 |
| Weight (kg) | 75 | 60 | 78.6 | 56 |
| Comorbidity |  |  |  |  |
| Diabetes mellitus | - | - | + | - |
| Hypertension | - | + | - | - |
| Chronic kidney disease | - | - | - | - |
| Cardiovascular disease | - | - | - | - |
| Before NM initiation |  |  |  |  |
| Laboratory data at NM initiation |  |  |  |  |
| WBC (/L) | 11.02 × 109 | 9.92 × 109 | 6.93 × 109 | 4.2 × 109 |
| Lym (%) | 18.8 | 8.3 | 9.5 | 12.8 |
| Hb (g/dL) | 10.2 | 11.2 | 12.4 | 12.9 |
| PLT (/L) | 345 × 109 | 465 × 109 | 129 × 109 | 222 × 109 |
| Lactate (mmol/L) | 1.33 | 0.97 | 1.85 | 0.55 |
| CRP (mg/dL) | 5.99 | 9.71 | 16.41 | 10.33 |
| AST (IU/L) | 110 | 116 | 50 | 52 |
| ALT (IU/L) | 197 | 174 | 26 | 24 |
| LDH (IU/L) | 403 | 469 | 678 | 611 |
| UN (mg/dL) | 17 | 21 | 30 | 6 |
| Cre (mg/dL) | 0.61 | 0.6 | 0.98 | 0.4 |
| APTT (s) | 35.0 | 56.1 | 49.4 | 32.8 |
| PT-INR | 0.97 | 1.23 | 1.22 | 1.05 |
| FDP (mcg/mL) | 19.9 | 21.0 | 6.6 | 5.0 |
| FDP-DD (mcg/mL) | 9.5 | 10.7 | 2.2 | 1.4 |
| Fbg (mg/dL) | 578 | 605 | 531 | 484 |
| p/f | 233 | 200 | 146 | 196 |
| Physical sign |  |  |  |  |
| Systolic blood pressure (mmHg) | 169 | 167 | 102 | 196 |
| Diastolic blood pressure (mmHg) | 80 | 75 | 53 | 108 |
| Heart rate (/min) | 117 | 95 | 118 | 82 |
| Respiratory rate (/min) | 29 | 20 | 18 | 15 |
| Body temperature (°C) | 37.1 | 37.7 | 38.7 | 37.2 |
| SOFA score | 3 | 2 | 6 | 3 |
| Support |  |  |  |  |
| Respiratory support | IMV | IMV | IMV | IMV |
| Prone position | + | + | - | - |
| VV-ECMO | - | - | + | + |
| During NM administration |  |  |  |  |
| NM [mg/(kg·h)] | 0.13 | 0.14 | 0.15 | 0.14 |
| Medication | Favipiravir, Dalteparin, Esomeprazole, Dexmedetomedine, Suvorexant, Ramelteon, Bromhexine, Mosapride | Favipiravir, Dalteparin, Esomeprazole, Suvorexant, Ramelteon, Pitavastatin, Amlodipine, Azilsartane | Dalteparin, Omeprazole, Dexmedetomedine, Propofol, Fentanyl, Midazolam, Bromhexine, Rocuronium, Noradrenaline, CTRX, AZM | Favipiravir, Esomeprazole, Omeprazole, Dexmedetomedine, Propofol, Fentanyl, Nardemedine |
| Intervention |  |  |  |  |
| K-intake decrease | - | + | - | + |
| Furosemide | - | - | - | + |
| Glucose-Insulin therapy | - | - | + | - |
| K net |  |  |  |  |
| K-intake [mEq/(kg·d)] | 0.90 | 1.07 | 0.34 | 0.81 |
| K-out (mEq/d) |  | 49.8 | 8.7 | 16.5 |
| K-balance (mEq/d) |  | 7.8 | 31.3 | 51.5 |

WBC: White blood cell; Lym: Lymphocytes; Hb: Hemoglobin; PLT: Platelet; CRP: C-reactive protein; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; LDH: Lactate dehydrogenase; UN: Urea nitrogen; Cre: Creatinine; APTT: Activated partial thromboplastin time; PT-INR: Prothrombin time and normalized ratio; FDP: Fibrin degradation products; FDP-DD: Fibrin degradation product D-dimer; Fbg: Fibrinogen; p/f: PaO2/FiO2; SOFA: Sequential organ failure assessment; VV-ECMO: Veno-venous extracorporeal membrane oxygenation; NM: Nafamostat mesylate; K: Potassium.